The Livzon-backed cancer and infectious disease therapy developer has added $40m to a round that will support the progression of its lead candidate toward clinical trials.

Elicio Therapeutics, a US-based immuno-oncology therapy developer backed by pharmaceutical group Livzon, has increased its series B round to $73m. The company raised $33m for the first close of the round in October 2019 but has not confirmed the identity of any of the participants, though it said the latest funding came from an international…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.